Skip to main content
. 2021 May 13;144(3):199–209. doi: 10.1161/CIRCULATIONAHA.121.054892

Table 2.

Change in Primary and Secondary Outcomes With Sacubitril/Valsartan or Valsartan From Baseline to Week 52

graphic file with name cir-144-199-g002.jpg